HDAC8-IN-1

Cat. No.:	HY-111342			
CAS No.:	1417997-93	-3		
Molecular Formula:	C ₂₂ H ₁₉ NO ₃			
Molecular Weight:	345.39			
Target:	HDAC			
Pathway:	Cell Cycle/DNA Damage; Epigenetics			
Storage:	Powder	-20°C	3 years	
		4°C	2 years	
	In solvent	-80°C	2 years	
		-20°C	1 year	

®

MedChemExpress

SOLVENT & SOLUBILITY

Preparing Stock Solutions		Solvent Mass Concentration	1 mg	5 mg	10 mg			
	1 mM	2.8953 mL	14.4764 mL	28.9528 mL				
		5 mM	0.5791 mL	2.8953 mL	5.7906 mL			
		10 mM	0.2895 mL	1.4476 mL	2.8953 mL			
	Please refer to the so	lubility information to select the ap	propriate solvent.					
n Vivo		one by one: 10% DMSO >> 40% PE g/mL (7.24 mM); Clear solution	G300 >> 5% Tween-8	0 >> 45% saline				
		l each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) ubility: ≥ 2.5 mg/mL (7.24 mM); Clear solution						
	nt one by one: 10% DMSO >> 90% corn oil mg/mL (7.24 mM); Clear solution							

BIOLOGICAL ACTIVITY				
Description	HDAC8-IN-1 is a HDAC8 inhibitor with an IC ₅₀ of 27.2 nM.			
IC₅₀ & Target	HDAC8 27.2 nM (IC ₅₀)			
In Vitro	HDAC8-IN-1 is a HDAC8 inhibitor with an IC ₅₀ of 27.2 nM in cancer cell lines. HDAC8-IN-1 (compound 22 d) shows antiproliferative effects toward several human lung cancer cell lines (A549, H1299, and CL1-5); HDAC8-IN-1 exhibits			

0 ||

Ĺ N_OH H MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cell Death Dis. 2021 May 18;12(6):501.
- Metab Eng. 2023 Sep 17:80:94-106.

See more customer validations on <u>www.MedChemExpress.com</u>

REFERENCES

[1]. Huang WJ, et al. Synthesis and biological evaluation of ortho-aryl N-hydroxycinnamides as potent histone deacetylase (HDAC) 8 isoform-selective inhibitors. ChemMedChem. 2012 Oct;7(10):1815-24.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA